Shots:
- Health Canada has approved Elahere under priority review to treat FRα+, Pt-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1-3 prior treatments
- Approval was based on P-III (MIRASOL) trial assessing Elahere vs investigator’s choice of CT in pts (n=453) to treat PROC expressing high levels of FRα, as determined using the Ventana FOLR1 RxDx Assay
- Trial showed reduction in progression or death risk by 35% & decrease in death risk by 33%, with ORR of 42% vs 16% (CR: 5% vs 0%)
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie’s Rinvoq (Upadacitinib) Receives the Health Canada Approval for Giant Cell Arteritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
